Oncotelic Q3 10-Q: Going Concern Warning, $16.8M Working Capital Deficit, $63,798 Cash
OTLC sits 19% above its 52-week low of $0.011.
Summary
Substantial doubt about its ability to continue as a going concern is disclosed in Oncotelic's Q3 2026 10-Q, with only $63,798 of cash, a $16.8 million working capital deficit, and a $3.06 million nine-month net loss — while the balance sheet rests on a $388 million non-cash fair-value mark on the GMP Bio joint venture.
Key Events · Earnings and Guidance · OTLC
-
Going Concern Warning Reiterated
Management states it does not believe the company has sufficient cash for twelve months from the date of this report and that substantial doubt exists about its ability to continue as a going concern.
-
Cash Down to $63,798
Cash was $63,798 at September 30, 2026 (total including $20,000 restricted cash: $83,798), down from $88,857 at December 31, 2025, against a negative working capital position of approximately $16.8 million.
-
Nine-Month Net Loss Widens to $3.06M
Net loss before non-controlling interests was $3,058,863 for the nine months ended September 30, 2026, versus $1,268,184 in the prior-year period, driven by $3.18 million of G&A including $2.44 million of stock-based compensation.
-
Balance Sheet Rests on $388M JV Mark
The $388,000,000 fair value of the 45% GMP Bio stake is a Level 3 non-cash valuation with no change recorded in Q3 2026; it provides no liquidity to the parent, and the JV's planned Hong Kong IPO is now targeted for Q2/Q3 2027.
Analysis · OTLC · Life Sciences
Management's going-concern warning is explicit in Oncotelic's Q3 2026 report: the company does not believe it has sufficient cash for twelve months from the date of this report. Cash stood at just $63,798 (plus $20,000 restricted) against a negative working capital position of roughly $16.8 million, and the nine-month net loss widened to $3.06 million from $1.27 million a year earlier. Almost the entire balance sheet rests on a $388 million Level 3 fair-value mark on the 45% GMP Bio joint venture stake — an asset that generates no cash for the parent and cannot be sold until the JV's planned Hong Kong IPO, now targeted for Q2/Q3 2027. The company also discloses that its convertible notes, preferred stock, warrants and options collectively exceed its authorized but unissued common shares, meaning a shareholder vote to raise the authorized share count is likely needed before further conversions can occur. Material weaknesses in internal control over financial reporting were flagged, and management concluded disclosure controls were not effective.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OTLC was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $6.1M. The 52-week trading range was $0.01 to $0.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.